ClearPoint Neuro Inc vs Williams-Sonoma, Inc. — how do they compare? ClearPoint Neuro Inc trades at $15.97 (market cap $478.63M), while Williams-Sonoma, Inc. trades at $222.29 (market cap $25.51B). The key difference: Williams-Sonoma, Inc. is far larger — about 53.3× ClearPoint Neuro Inc's market cap, and Williams-Sonoma, Inc. pays a 1.4% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | WSM | |
|---|---|---|
Market Cap | $478.63M | $25.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.60 | $240.06 |
52-Week Low | $8.66 | $163.62 |
Enterprise Value | $506.63M | $26.35B |
Dividend Yield | — | 1.4% |
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
Williams-Sonoma (WSM) trades at $216.65, down 2.3% on the day, with a bullish technical outlook supported by moving averages but mixed oscillators. The company demonstrates strong profitability with a 13.81% net margin and 54.01% ROE, though revenue has declined slightly from $8.7B in 2023 to $7.7B in 2025. Recent quarterly earnings have consistently beaten estimates, and the company maintains active brand collaborations and dividend payments.
The stock presents a balanced outlook with solid fundamentals and analyst consensus near the current price, but faces risks from revenue volatility and competitive pressures. Upside potential exists if earnings momentum continues, while macroeconomic headwinds and retail sector challenges pose downside risks.
Trailing returns across standard periods
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →